WASHINGTON — The Supreme Court will hear arguments about access to the abortion medication mifepristone on March 26.
The lawsuit is the first major test of abortion limits to go before the highest court since the same panel overturned federal abortion rights in June 2022. It also could have massive ramifications for the Food and Drug Administration’s authority.
The FDA approved mifepristone in 2000 to be used within the first seven weeks of pregnancy. Sixteen years later, it extended that approval to 10 weeks of pregnancy. The Biden administration in 2021 removed requirements that the pill had to be taken in-person with a provider, opening the door to mail-order prescriptions.
About the Author Reprints
To submit a correction request, please visit our Contact Us page.
STAT encourages you to share your voice. We welcome your commentary, criticism, and expertise on our subscriber-only platform, STAT+ Connect